Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 5% After Insider Selling

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) fell 5% on Friday following insider selling activity. The stock traded as low as $3.54 and last traded at $3.5350. 3,552,628 shares were traded during mid-day trading, a decline of 83% from the average session volume of 21,216,084 shares. The stock had previously closed at $3.72.

Specifically, CFO Ben R. Taylor sold 13,426 shares of the business’s stock in a transaction on Wednesday, February 18th. The stock was sold at an average price of $3.08, for a total transaction of $41,352.08. Following the sale, the chief financial officer directly owned 1,195,349 shares in the company, valued at approximately $3,681,674.92. The trade was a 1.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on RXRX. Morgan Stanley set a $11.00 target price on Recursion Pharmaceuticals in a report on Wednesday, December 17th. UBS Group set a $11.00 price target on shares of Recursion Pharmaceuticals in a report on Wednesday, December 17th. JPMorgan Chase & Co. upgraded Recursion Pharmaceuticals from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $10.00 to $11.00 in a research report on Wednesday, December 17th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Recursion Pharmaceuticals in a research report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Recursion Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $9.40.

Recursion Pharmaceuticals Stock Down 4.2%

The company has a quick ratio of 4.60, a current ratio of 4.60 and a debt-to-equity ratio of 0.01. The stock has a 50-day simple moving average of $4.27 and a two-hundred day simple moving average of $4.78. The firm has a market cap of $1.85 billion, a PE ratio of -1.96 and a beta of 0.95.

Institutional Trading of Recursion Pharmaceuticals

A number of hedge funds have recently bought and sold shares of RXRX. Brighton Jones LLC grew its position in Recursion Pharmaceuticals by 49.4% during the fourth quarter. Brighton Jones LLC now owns 20,261 shares of the company’s stock valued at $137,000 after acquiring an additional 6,699 shares during the last quarter. Royal Bank of Canada boosted its stake in shares of Recursion Pharmaceuticals by 627.6% in the 1st quarter. Royal Bank of Canada now owns 269,013 shares of the company’s stock valued at $1,423,000 after purchasing an additional 232,038 shares in the last quarter. AQR Capital Management LLC purchased a new stake in shares of Recursion Pharmaceuticals in the 1st quarter valued at $890,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Recursion Pharmaceuticals by 7.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 177,434 shares of the company’s stock valued at $953,000 after purchasing an additional 12,372 shares during the last quarter. Finally, Focus Partners Wealth purchased a new position in Recursion Pharmaceuticals in the 1st quarter worth $77,000. Institutional investors own 89.06% of the company’s stock.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed.

At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations.